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Background: Liver resection for hepatocellular carcinoma (HCC) has the highest local controllability among all local
treatments and results in a good survival rate. However, the recurrence rates of HCC continue to remain high even
after curative hepatectomy Moreover, it has been reported that some patients with HCC have an early death due to
recurrence. We analyzed the preoperative risk factors for early cancer death.
Methods: Between 1997 and 2009, 521 consecutive patients who underwent hepatectomy for HCC at our center
were assigned to group ED (death due to HCC recurrence or progression within 1 year after hepatectomy) and
group NED (alive over 1 year after hepatectomy). Risk factors for early cancer death were analyzed.
Results: Group ED included 48 patients, and group NED included 473 patients. The cause of death included cancer
progression (150; 78.1%), operation-related (1; 0.5%), hepatic failure (15; 7.8%), and other (26; 13.5%). Between the ED
and NED groups, there were significant differences in albumin levels, Child-Pugh classifications, anatomical
resections, curability, tumor numbers, tumor sizes, macroscopic vascular invasion (portal vein and hepatic vein),
alpha-fetoprotein (AFP) levels, AFP-L3 levels, protein induced by vitamin K absence or antagonism factor II (PIVKA-II)
levels, differentiation, microscopic portal vein invasion, microscopic hepatic vein invasion, and distant metastasis by
univariate analysis. Multivariate analysis identified specific risk factors, such as AFP level> 1,000 ng/ml, tumor
number≥ 4, tumor size≥ 5 cm, poor differentiation, and portal vein invasion. With respect to the preoperative risk
factors such as AFP level, tumor number, and tumor size, 3 (1.1%) of 280 patients with no risk factors, 12 (7.8%) of
153 patients with 1 risk factor, 24 (32.9%) of 73 patients with 2 factors, and 9 (60.0%) of 15 patients with 3 risk
factors died within 1 year of hepatectomy (p< 0.0001).
Conclusions: Hepatectomy should be judiciously selected for patients with AFP level> 1,000 ng/ml, tumor
number≥ 4, and tumor size≥ 5 cm, because patients with these preoperative risk factors tend to die within 1 year
after hepatectomy; these patients might be better treated with other therapy.
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Liver resection for the treatment of hepatocellular car-
cinoma (HCC) has the highest controllability among all
local treatments and results in a good survival rate [1,2].
However, recurrence rates remain high and are the main
cause of early death even after curative hepatectomy [3].
Moreover, it has been reported that some patients with
HCC have an early death due to recurrence [4]. In the
remnant liver after hepatectomy, tumor recurrence is
recognized as intrahepatic metastasis caused by dissem-
ination of cells in the portal vein or metachronous multi-
centric hepatocarcinogenesis [5]. The risk factors for
early recurrence are reported to be related to tumor cell
dissemination due to tumor characteristics such as vas-
cular invasion [6,7] and intrahepatic metastasis [8].
Though the two algorithms that were proposed from the
Barcelona Clinic Liver Cancer (BCLC) classification [9]
and Japanese guideline [10] recommend that multiple
HCCs be treated by transcatheter arterial chemoemboli-
zation with lipiodol (TACE) or sorafenib, hepatectomy
beyond these algorithms was actually performed in the
clinical scene. However, the risk factors for early death
due to HCC recurrence or progression within 1 year
after hepatectomy have not been clearly evaluated [11].
On the other hand, the Sorafenib Hepatocellular Car-
cinoma Assessment Randomized Protocol (SHARP) trial
[12] recently reported the effectiveness of sorafenib in
the treatment of advanced HCC. In this report, median
overall survival was 10.7 months in the sorafenib group
and 7.9 months in the placebo group. If patients have an
early death within 1 year due to recurrence after hepa-
tectomy, there might be no benefit of hepatectomy com-
pared to sorafenib. Therefore, the risk factors for early
death within 1 year after hepatectomy due to HCC re-
currence or progression should be evaluated, and the ap-
propriateness of hepatectomy for patients with advanced
HCC should be investigated.
To identify the risk factors related to early death after
hepatectomy, we analyzed the outcomes of 521 consecu-
tive patients who underwent primary hepatectomy for
HCC at our center.
Methods
Patients
Between January 1997 and May 2009, 521 consecutive
patients underwent hepatectomy for HCC at our center.
These patients were followed for at least 1 year, and then
assigned to group ED (death due to HCC recurrence or
progression within 1 year after hepatectomy) or group
NED (alive over 1 year after hepatectomy). The resulting
ED group included 48 (9.2%) patients, and the resulting
NED group included 465 (89.3%) patients. Of all 521
patients, 8 (1.5%) patients who died of liver failure, other
causes, and postoperative complications within 1 yearafter hepatectomy were excluded from group ED and
NED. The mean age of 513 patients of group ED and NED
was 61.3 years, with a range of 18–87 years. Of the 513
patients, 427 (83.2%) were male and 86 (16.8%) were fe-
male, 221 (43.1%) were hepatitis B virus surface antigen-
positive, 189 (36.8%) were hepatitis C virus antibody-
positive, and 175 (34.1%) had cirrhosis. At least 2 weeks
before hepatectomy, imaging studies were performed and
preoperative serum alpha-fetoprotein (AFP), Lens culinaris
agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3),
and protein induced by vitamin K absence or antagonism
factor II (PIVKA-II) levels were simultaneously measured
using standard methods. Among the 513 patients, 499
(97.3%) were categorized as Child-Pugh class A (Table 1).
The patients were followed up for a median of 84.2
months (range, 12.5–165.0 months). This study was
approved by the Institutional Review Board of the Hok-
kaido University, School of Advanced Medicine.
Hepatectomy
Anatomical resection is defined as a resection in which
lesion(s) are completely removed anatomically on the
basis of Couinaud’s classification (segmentectomy, sec-
tionectomy, and hemihepatectomy or extended hemihe-
patectomy) in patients with sufficient functional reserve.
Non-anatomical partial resection was performed as a
limited resection or tumor enucleation. When R0 resec-
tions were performed, the resection surface was found to
be histologically free of HCC. Indocyanine green reten-
tion rates at 15 min (ICGR15) were measured to evaluate
liver function reserve, regardless of the presence or ab-
sence of cirrhosis.
HCC recurrence
Every 3 months for the first 2 years after hepatectomy,
the patients underwent follow-up evaluations comprising
liver function tests, measurements of tumor markers
AFP and PIVKA-II, ultrasonography (US), and dynamic
computed tomography (CT). After 2 years, routine CT
was performed only once every 4 months. If recurrence
was suspected, CT and magnetic resonance imaging
(MRI) were performed; if necessary, CT during angiog-
raphy and bone scintigraphy were also performed. This
enabled precise diagnoses of the site, number, size, and
invasiveness of the recurrent lesions.
Statistical analysis
Patient survival (PS) rates were determined via the
Kaplan-Meier method. Univariate analysis was performed;
then multivariate analysis and logistic regression were per-
formed only on significant variables. Statistical analyses
(StatView 5.0 for Windows: SAS Institute Inc., Cary, NC)
were performed using standard tests (X2, t-test) where ap-
propriate. Significance was defined as p< 0.05.
Table 1 Univariate analysis of the risk factors of death






Sex Male 40 387
Female 8 78 0.9849
Age <60 24 211
60≤ 24 254 0.5405
HBV + 26 195
- 22 270 0.1033
HCV + 14 175
- 34 290 0.2469
Albumin <4 33 214
(g/dl) 4≤ 15 251 0.0027
Total bilirubin <0.8 32 283
(mg/dl) 0.8≤ 16 182 0.4314
ICGR15 (%) <15 27 250
15≤ 21 215 0.7421
Child-Pugh A 42 457
B 6 8 <0.0001
AFP (ng/ml) ≤200 15 355
200<, ≤1,000 5 37
1,000< 28 73 <0.0001
AFP-L3 (%) ≤15 23 334
15%< 40< 5 49
40< 20 83 0.0002
PIVKA-II (mAU/ml) ≤100 10 258
100<, ≤1,000 8 93
1,000< 30 114 <0.0001
Liver cirrhosis Present 17 158
Absent 31 307 0.8414
Curability R0 R1 40 443
R2 8 22 0.0008
Anatomical resection Yes 42 326
No 6 139 0.0108
Tumor number 1 16 321
2, 3 11 113
4≤ 21 31 <0.0001
Tumor size ≤2 cm 4 64
2-5 cm 6 254






Present 20 25 <0.0001
Differentiation Well 0 50
Moderate 19 308
Poor 29 92
Necrosis 0 15 <0.0001
Table 1 Univariate analysis of the risk factors of death














vv3 3 4 <0.0001
Distant metastasis Absent 43 459
Present 5 6 <0.0001
HCC: hepatocellular carcinoma.
NED: alive 1 year after hepatectomy.
ED: death due to HCC recurrence or progression within 1 year after
hepatectomy.
HBV: hepatitis B virus s antigen.
HCV: anti-hepatitis C virus antibody.
ICGR15: indocyanin green retention rate at 15 min.
AFP: alpha-fetoprotein.
AFP-L3: Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein.
PIVKA-II: protein induced by vitamin K absence or antagonism factor II.
vp0: no tumor thrombus in the portal vein.
vp1: tumor thrombus distal to the second branches of the portal vein.
vp2: tumor thrombus in the second branches of the portal vein.
vp3: tumor thrombus in the first branch of the portal vein.
vp4: tumor thrombus extension to the trunk or the opposite side branch of
the portal vein.
vv0: no tumor thrombus in the hepatic vein.
vv1: tumor thrombus in a branch of the hepatic vein.
vv2: tumor thrombus in the right, middle, or left hepatic vein trunk or the
short hepatic vein.
vv3: tumor thrombus to the inferior vena cava.
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Causes of death
PS rates (n= 521) at 1, 2, 5, and 10 years were 90.5%,
84.6%, 69.0%, and 54.2%, respectively (Figure 1), with
192 deaths (36.9%). The causes of death, whether within
1 year post-hepatectomy or later, included HCC recur-
rence or progression (n= 150; 78.1%), liver failure
(n= 15; 7.8%), other causes (n= 26; 13.5%), and post-
operative complications (n= 1; 0.5%). Of the 150 patients
who died of HCC recurrence or progression, 48 (32.0%)
died within 1 year after hepatectomy (Figure 2). The
patients who died of liver failure (n= 4), other causes
(n= 3), and postoperative complications (n= 1) within 1
year after hepatectomy were excluded from group ED
and NED.Clinicopathological characteristics and operative variables
Patient characteristics and perioperative outcomes are
shown in Table 1. Between the ED and NED groups,
Figure 1 Survivals of all 521 patients at 1, 2, 5, 7, and 10 years
were 90.5%, 84.6%, 69.0%, 60.8%, and 54.2%, respectively.
Table 2 Logistic regression analysis based on univariate
analysis of the risk factors of death from cancer
progression within 1 year after hepatectomy
Risk factor p Risk ratio 95% CI
AFP(ng/ml):>1,000(vs.≤ 200) 0.0079 4.098 1.447-11.628
Tumor number 4≤ (vs. 1) 0.0208 3.535 1.206-10.361




vp1(vs. vp0) 0.0037 5.02 1.691-14.909
vp2(vs. vp0) 0.0034 8.507 2.029-35.667
AFP: alpha-fetoprotein.
vp0: no tumor thrombus in the portal vein.
vp1: tumor thrombus distal to the second branches of the portal vein.
vp2: tumor thrombus in the second branches of the portal vein.
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Child-Pugh classifications, anatomical resections, cur-
ability, tumor numbers, tumor sizes, macroscopic vascu-
lar invasion (portal vein and hepatic vein), AFP levels,
AFP-L3 levels, PIVKA-II levels, differentiation, micro-
scopic portal vein invasion, microscopic hepatic vein in-
vasion, and distant metastasis. Tumor-related factors are
also shown in Table 1. When the risk factors that were
identified as significant by univariate analysis were
included in a multivariate analysis via logistic regression,
it was found that AFP level, tumor number, tumor size,
differentiation, and microscopic portal vein invasion
were independent risk factors for early death due to
HCC recurrence or progression within 1 year after hepa-
tectomy (Table 2).Figure 2 The number of patients who died of HCC recurrence
or progression after hepatectomy. Of the 150 patients who died
of HCC recurrence or progression, 48 patients (32.0%) died within 1
year after hepatectomy.Risk factors for early death
Independent, preoperatively evaluable risk factors for
early death were identified by multivariate analysis as
AFP> 1,000 ng/ml, tumor number ≥ 4, and tumor size ≥
5 cm. The patients of group ED and NED (n= 513) were
categorized into three levels of risk: risk 0 if they had no
risk factors (n= 276), risk 1 if they had any one risk fac-
tor (n= 151), risk 2 if they had any two risk factors
(n= 71), and risk 3 if they had all three risk factors
(n= 15). In risk 0, 3 patients (1.1%), in risk 1, 12 patients
(7.9%), in risk 2, and 24 patients (33.8%); in risk 3, 9
patients (60.0%) died within 1 year after hepatectomy
(p< 0.0001) (Table 3). PS rates for risk 0, risk 1, risk 2,
and risk 3 at 1 year were 98.9%, 91.7%, 66.1%, and 40.0%,
respectively (Figure 3). Multivariate analysis showed that
the risk ratio of risk 1 vs. risk 0 was 7.856, that of risk 2
vs. risk 0 was 46.468, and that of risk 3 vs. risk 0 was
136.5 (Table 3).
Discussion
When the patients were categorized by the number of
independent, preoperatively evaluable risk factors, theTable 3 Logistic regression analysis of three risk levels of
death from cancer progression within 1 year after
hepatectomy
No. of patients No. of ED (%) Risk ratio 95% CI
Risk 0 276 3 (1.1) 1
Risk 1 151 12 (7.9) 7.856 2.181-28.302
Risk 2 71 24 (33.8) 46.468 13.452-160.514
Risk 3 15 9 (60.0) 136.5 29.354-634.752
HCC: hepatocellular carcinoma.
ED: death due to HCC recurrence or progression within 1 year after
hepatectomy.
Risk 0: they had no risk factors.
Risk 1: they had any 1 risk factor.
Risk 2: they had any 2 risk factors.
Risk 3: they had all 3 risk factors.
Risk factors: AFP> 1,000 ng/ml, tumor number≥ 4, and tumor size≥ 5 cm.
Figure 3 PS rates for risk 0, risk 1, risk 2, and risk 3 at 1 year
were 98.9%, 91.7%, 66.1%, and 40.0%, respectively. PS rates for
risk 0, risk 1, risk 2, and risk 3 at 1 year were 85.4%, 61.5%, 31.4%, and
22.2%, respectively.
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three risk factors: AFP> 1,000 ng/ml, tumor number ≥ 4,
and tumor size ≥ 5 cm, while the early death rate was
1.1% for patients with no risk factors. Therefore, the ap-
propriateness of hepatectomy for HCC should be care-
fully examined for patients who have large and multiple
HCC with high AFP levels; these patients might be better
treated with other therapeutic options, such as TACE or
sorafenib.
Early recurrence is the main cause of early death
within 1 year after hepatectomy. The risk factors for
early recurrence are reported to be related to tumor cell
dissemination due to tumor characteristics such as vas-
cular invasion [6,7] and intrahepatic metastasis [8]. Be-
cause these factors are diagnosed only by postoperative
pathological examination, preoperatively evaluable fac-
tors are necessary to decide the appropriateness of hepa-
tectomy in advanced HCC. Among preoperative risk
factors, an HCC tumor larger than 5 cm is reported to
be an important indicator of a high risk of recurrence
after resection [13] and has a higher incidence of intra-
hepatic metastasis and portal venous invasion [14,15].
Therefore, it is believed that an HCC tumor larger than
5 cm has high malignant potential. In this study and an-
other report [11], tumor size ≥ 5 cm reflected this high
malignant potential and was selected as an independent
risk factor for early death due to HCC recurrence or pro-
gression within 1 year after hepatectomy.
Multivariate analysis also shows that tumor number is
an important predictor of recurrence. Lai et al. [16]
reported that the presence of multiple nodules was the
most powerful predictor of both long-term survival and
tumor recurrence. Because multiple HCC originates
from disseminated cancer cells and not from multicentriccarcinogenesis, multiple HCC is a more aggressive pheno-
type than solitary HCC. Yang reported that, after resection
of solitary large HCC, the clinical and pathological charac-
teristics and outcome are similar to those of small HCC,
but are significantly better than those of nodular HCC
(node number≥ 2) [17]. It has also been reported that the
expression levels of some human genes closely related to
invasion and metastasis were significantly lower in solitary
large HCC than in nodular HCC [17,18]. They proposed
solitary large HCC as a specific subtype, less malignant
than nodular HCC. Moreover, in multiple HCC, it was
speculated that latent tumors, intrahepatic micrometas-
tases that might be subsequently found to produce early
recurrent tumors, could already be present in the remnant
liver at the time of surgery. Therefore, tumor number≥ 4
was selected in the current study as a significant factor
predicting early death after hepatectomy.
In our study, multivariate analysis showed that an AFP
level over 1,000 ng/ml was an independent factor related
to early death. Previous reports have shown that AFP is
an independent predictor of prognosis [19], even in
patients who had undergone hepatectomy [20]. High
levels of AFP in fully developed HCC or in the serum of
the host are associated with more aggressive behavior
and increased anaplasis [21]. On the other hand, it is
well known that AFP levels may increase in some
patients with acute and chronic hepatitis without HCC
[22,23] and that elevation of AFP levels correlates with
inflammation caused by background diseases and hep-
atocyte regeneration [24]. However, because the eleva-
tion of AFP levels by hepatitis or regeneration is usually
not so high, only 200 ng/ml [25], AFP levels over 1,000
ng/ml might specifically indicate tumor malignancy.
Yamanaka et al. [26] also reported that the serum AFP
value per tumor diameter was the most significant risk
factor for early death within 1 year after resection in
patients with stage II–III HCC by multivariate analysis.
Given these preoperatively evaluable risk factors, the
probability of early death after hepatectomy can be esti-
mated by the number of risk factors. In risk 0, 3 patients
(1.1%), in risk 1, 12 patients (7.9%), in risk 2, 24 patients
(33.8%), and in risk 3, 9 patients (60.0%) died within 1
year after hepatectomy. The risk ratio of risk 1 vs. risk 0
was 7.856, that of risk 2 vs. risk 0 was 46.468, and that of
risk 3 vs. risk 0 was 136.5 by multivariate analysis. PS
rates for risk 3 at 1 year were 40.0%, while in the SHARP
trial, survival rates at 1 year were 44% in the sorafenib
group [12]. Moreover, Takayasu et al. reported that the
survival rate at 1 year of patients with ≥ 4 tumors, ≥5.1
cm in diameter was 74% [27]. In this way, because the
surgical outcome of patients with all three risk factors
was worse than that of the patients treated with sorafe-
nib or TACE, these patients might be better treated with
other therapeutic options than hepatectomy for the first
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and 2 who might be beyond BCLC and Japanese algo-
rithms should not be excluded from hepatectomy be-
cause of their good outcome: 91.7%, 66.1% at 1 year of
PS.
On the other hand, in this study, macroscopic vascular
invasion (portal and hepatic veins) was not indicated by
multivariate analysis as an independent risk factor
related to early death. It has been reported that the prog-
nosis of patients with portal vein tumor thrombus
(PVTT) in the main trunk or first branch is very poor;
the median survival period of patients with portal throm-
bosis is only 2.7 months without appropriate treatment
[28]. However, recently reported patients showed long-
term survival rates when hepatectomy was combined
with pre- or postoperative treatment. We reported the
efficacy of a combination of hepatectomy and preopera-
tive radiotherapy for PVTT in the main trunk or first
branch. The 1-, 3-, and 5-year survival rates in hepatec-
tomized patients with preoperative radiotherapy for
PVTT were 100%, 53.3%, and 40.0%, respectively [29].
Minagawa [30] reported that the survival rate of patients
with PVTT, including those who underwent hepatic re-
section with preoperative transcatheter arterial che-
moembolization, was 42% at 5 years. Nagano [31]
reported that 15 patients with HCC with PVTT were
treated with FU arterial infusion and interferon therapy
(FAIT) and surgery, and that all the patients (100%) sur-
vived over 1 year; without FAIT and surgery, 10 patients
(67%) died within 1 year. Therefore, even if patients have
HCC with macroscopic vascular invasion, particularly
PVTT in the main trunk or first branch, hepatectomy is
not contraindicated in these patients when combined
with pre- or postoperative treatment. In the patients with
risk 0, 1, of 45 patients 19 had macroscopic vascular in-
vasion. Of these 19 patients, only 5 (26.3%) died within 1
year after hepatectomy. In the 26 patients with risk 2, 3,
15 patients (57.7%) died within 1 year after hepatectomy.
Concerning Child-Pugh B cirrhosis, the high-risk
patients could be also indentified. From these data,
though macroscopic vascular invasion and Child-Pugh B
cirrhosis were poor prognostic factors, the patients who
had these factors did not always die in 1 year after hepa-
tectomy. Using our risk levels, the patients with ex-
tremely poor prognosis could be identified from the
patients who had poor prognostic factors such as macro-
scopic vascular invasion or Child-Pugh B. Therefore,
concerning risk levels, risk 0 to 3 was very important
and useful for predicting the prognosis of patients with
HCC who underwent hepatectomy.
Conclusions
In conclusion, the appropriateness of hepatectomy in
the treatment of HCC should be carefully consideredwhen patients have the following preoperative risk fac-
tors: AFP> 1,000 ng/ml, tumor number ≥ 4, and/or
tumor size ≥ 5 cm; these patients might be better treated
with other therapeutic options, i.e., sorafenib and TACE.
However, even if patients have HCC with PVTT in the
main trunk or first branch, hepatectomy is not contrain-
dicated when combined with pre- or postoperative
treatment.
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